Inogla M

Lactic acidosis associated with Inogla M treatment is a rare but fatal adverse effect. Lactic acidosis appears to result from biguanide interference causing an increase in production and decrease in clearance of lactate leading to higher cellular lactate levels. A decrease in pyruvate carboxylase activity, the rate-limiting enzyme in the formation of glucose from lactate, can also decrease hepatic metabolism of lactate. leading to increasing lactic acidosis. Signs and symptoms of Inogla M induced lactic acidosis are nonspecific and include anorexia, nausea, vomiting, altered level of consciousness, hyperpnoea, abdominal pain, and thirst. 

Inogla M increases the sensitivity of insulin, young women with PCOS often have elevated insulin levels and are more likely to develop diabetes. It is often prescribed for women with PCOS to help prevent diabetes. A lifestyle that includes healthy nutrition and daily exercise is the most important part of a PCOS treatment plan.

Inogla M should be taken with food to reduce stomach and bowel side effects, which may experience the first few weeks of treatment. Also, exercise regularly and test for sugar in your blood or urine as directed.

Inogla M contain metformin, is an oral antidiabetic drug which belongs to the class of biguanide. It is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. Moreover, it also reduces the risk of cardiovascular complications of diabetes.

Inogla M helps in weight loss by reducing appetite and food intake. It also increases the insulin sensitivity in your body to work more effectively. This lead to decreased glucose production increases the use of glucose and decrease the fat deposition further helps in weight loss. However, Inogla M is not approved for weight loss, this is an off-label use.